Loading clinical trials...

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

Glycemic Effects of Nebivolol Compared With Metoprolol Extended Release and Compared With Hydrochlorothiazide In Hypertensive Patients With Type 2 Diabetes Mellitus: A Pilot Study

NCT00744237•Forest Laboratories

View on ClinicalTrials.gov

Summary

This study will evaluate the effects of nebivolol on glycemic control compared with metoprolol and HCTZ in patients with hypertension and type 2 diabetes mellitus

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female, 18-85 years of age
•Blood pressure in the range of 130 to 179/80 to 109 mmHg
•Currently using either an ACE inhibitor or an ARB alone or (an ACE inhibitor or an ARB and up to two other drugs for treatment of high blood pressure). (Patients may be on both an ACE inhibitor and ARB, but would need to be taken off one.)
•Stable medication regimen for high blood pressure for at least one month prior to screening
•Stable type 2 diabetes mellitus for at least 3 months prior to screening that is controlled by any or all of the following: diet and antidiabetic medications that may include fixed-dose insulin
•HgbA1c 6.5 to 8.5% (This is measured at the screening visit)

Exclusion Criteria

•Use of any beta blocker within one month prior to screening
•Use of clonidine within 3 months prior to screening
•Diagnosis of hyperthyroidism as evidenced by abnormal lab markers
•Any disorder requiring the intermittent or chronic use of systemic corticosteroids
•Diagnosis of hyperthyroidism as determined by lab markers done at screening
•Active liver disease as determined by lab markers
•Kidney impairment; estimated GFR \< 60 mL/min/1.73 m2
•History of heart attack, clinically significant arrhythmia, unstable angina, coronary angioplasty/bypass surgery, stroke, or TIA in 3 months prior to screening
•Chronic heart failure
•Drug or alcohol abuse within 2 years prior to screening
+2 more criteria

Locations (65)

Forest Investigative Site 15

Athens, Alabama, United States

Forest Investigative Site 16

Huntsville, Alabama, United States

Forest Investigative Site 35

Bell Gardens, California, United States

Forest Investigative Site

Buena Park, California, United States

Forest Investigative Site 54

Chino, California, United States

Forest Investigative Site 40

Fremont, California, United States

Forest Investigative Site

Palm Springs, California, United States

Forest Investigative Site

Pomona, California, United States

Forest Investigative Site 55

Sacramento, California, United States

Forest Investigative Site 11

San Diego, California, United States

Key Dates

Start Date

August 1, 2008

Primary Completion Date

July 1, 2010

Last Updated

July 29, 2011

Enrollment

231

ACTUAL participants

Conditions

HypertensionType 2 Diabetes Mellitus

Interventions

Nebivolol

DRUG

Metoprolol ER

DRUG

HCTZ

DRUG

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITINGNA

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 29, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

Feasibility of a Tailored Online Self-compassion Intervention

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart